In COVID-19 clinical update #124, Dr. Griffin discusses the results of a variant vaccine booster trial, the neutralization of variant sub-lineages by Novavax, the CDC’s recommendation of Novavax’s COVID-19 vaccine in adults, Paxlovid in patients who are immunocompromised and hospitalized, and inhaled fluticasone for outpatient treatment.

In COVID-19 clinical update #123, Dr. Griffin discusses rapid diagnostic testing in response to the monkeypox outbreak, leading causes of death in the US during the COVID-19 pandemic, antibody evasion by subvariants, broadly-neutralizing antibodies against emerging variants, factors associated with severe outcomes among hospitalized immunocompromised adults, measurement of the burden of hospitalizations during the pandemic, parental vaccine hesitancy in diverse communities, evaluating saliva sampling to improve access to diagnosis in low-resource settings, oral sabizabulin for high-risk hospitalized adults, lower-risk of multisystem inflammatory syndrome in children, and neurovascular injury with complement activation and inflammation during infection.

In COVID-19 clinical update #122, Dr. Griffin discusses vaccine availability and coverage among children, post-infection health impairments in children and adolescents, infection detection using salvia and nasopharyngeal samples, effectiveness of vaccines during delta dominance, durability…

In COVID-19 clinical update #121, Dr. Griffin discusses age as a risk factor for severe disease, updated vaccine boosters for the fall, pediatric infection and antibody seroprevalence in Arkansas over the first year of the COVID-19 pandemic, all-cause maternal mortality in the United States before and during the pandemic, and the effect of 2-week interruption in methotrexate treatment and how it impacts vaccine immunity.

In COVID-19 clinical update #120, Dr. Griffin discusses outcomes of SARS-CoV-2 reinfection, CDC recommendation for vaccines in young children, neurodevelopment outcomes in infants of mothers testing positive for COVID during pregnancy, efficacy of monoclonal antibodies and antivirals in hamsters, rebound phenomenon after PAXLOVID in high-risk persons, hospitalization for infection after PAXLOVID treatment, and risk of long COVID with different variants.

In COVID-19 clinical update #119, Dr. Griffin reviews tixagevimab for infection prevention, ivermectin for outpatient infection treatment, symptom rebound after PAXLOVID treatment, bamlanivimab minimally impacting immune response to vaccination, in-hospital mortality among infection patients, residual viral antigen in patients following infection, usage of Casirvimab/Imdevimab and Remdesivir in infected patients with depleted B-cells, and rheumatic symptoms following infection.

In COVID-19 clinical update #118, Dr. Griffin discusses management of hair loss after infection, FDA announcements on vaccine schedule and recommendations, Moderna announcement on bivalent booster candidate, association between vaccination and infection during pregnancy, population-level implications of Israel’s booster campaign, PAXLOVID outcomes during recent infection surge, efficacy and safety of Tixagevimab-cilgavimab, diagnostic accuracy of infection by canines, efficacy of colchicine in hospitalized patients, and factors associated with hospital readmission.  

In COVID-19 clinical update #117, Dr. Griffin discusses duration of virus shedding, association between pre-exposure to steroids and infection outcome, post-infection subtypes, rehabilitation for post-acute infection, Tixagevimab/Cilgavimab for infection prevention, antibody prophylaxis and vaccination in kidney transplant recipients, remdesivir and bebtelovimab fact sheets for providers, the updated guidelines on treatment with Famotidine, Paxlovid rebound symptom characterizations, antigen test positivity duration, viral dynamics of variants and isolation, association of inflammation in CS fluid, and transmission dynamics in Ghana.